2025-05-06-艾昆纬-中国医疗技术市场导航（英）_11页_3mb

Summary of Navigating China's MedTech Market White Paper

Core Content

This white paper provides an in-depth analysis of the current state and future trajectory of China's MedTech market, focusing on the interplay between financial pressures, regulatory reforms, and emerging opportunities. It highlights how MedTech companies, both local and multinational, can adapt and thrive in this evolving landscape.

Main Points

1. China's MedTech Market Overview

• China is the world's second-largest medical device market, with high growth expectations.
• The market is complex, with significant challenges for MedTech firms.
• The white paper aims to guide companies in navigating the regulatory and financial changes.

2. Financial Pressures on Public Medical Insurance

• Total health expenditure in China is increasing but remains below the OECD median at around 7% of GDP.
• The Basic Medical Insurance (BMI) fund faces reduced income growth due to the slowdown in economic growth.
• The National Healthcare Security Administration (NHSA) is implementing reforms to control costs, including:
  • Volume-Based Procurement (VBP): Reduces listing prices of medical consumables and drugs.
  • DRG Payment Reforms: Aims to curb excessive medical expenses.
  • Price Adjustments for Medical Service Items: Optimizes BMI fund expenditure structure.

3. Volume-Based Procurement (VBP)

• VBP has expanded to include high-value, low-value consumables, equipment, and IVD reagents.
• The policy uncertainty is decreasing, and MedTech companies are adjusting expectations.
• VBP is expected to continue, but at a more stable and gradual pace.
• The price of coronary stents (~$100) and PIVCs (~$0.60) has already created cost pressures.
• By 2024, over 70 medical consumables were included in VBP, and DRG coverage is expected to reach nearly 100% of regions.

4. Cost-Control Measures and Quality Concerns

• VBP is seen as a turning point in BMI cost control, but concerns about quality and efficacy of reduced-price products have emerged.
• Public hospitals and patients worry about the impact of price cuts on treatment outcomes and product quality.
• Despite these concerns, the NHSA and NMPA have provided comprehensive responses, indicating continued reform efforts.

5. Embracing Innovation

• The Chinese government supports innovation in medical technology, with an accelerated approval process for innovative devices.
• In 2024, the NMPA approved 65 innovative medical device products.
• Reimbursement for highly innovative and cost-effective devices is increasing, especially in economically developed regions.
• Digitalization is reshaping the MedTech landscape, with AI-powered diagnosis, imaging, and surgical robots redefining medical innovation.
• MedTech firms are advised to emphasize technological and clinical value in their competition strategies.

6. Private Healthcare as a Growing Opportunity

• Private healthcare, including commercial insurance and private hospitals, is being encouraged to complement public coverage.
• The government is piloting foreign-owned hospitals in major cities and promoting commercial insurance payments.
• While the private sector is still limited, it is expected to grow as public reforms reach a "turning point."
• Commercial insurance coverage is less than 10% of out-of-pocket medical expenses, but this is increasing.

7. Regulatory Uncertainty and Strategic Adaptation

• Multinational MedTech companies face regulatory challenges but also have substantial opportunities.
• Strategies to thrive include:
  • Localizing supply chains
  • Investing in innovation
  • Forming strategic collaborations
  • Leveraging commercial insurance
  • Monitoring private healthcare markets
• Examples include Medtronic, GE, Mölnlycke, and Siemens Healthineers, which have adopted these strategies.

8. The Road Ahead

• The Chinese government is establishing a "dual track" medical system, inspired by European models.
• This system includes:
  • A public system to ensure basic healthcare for all at lower costs.
  • A private system for middle- and high-income individuals.
• MedTech companies must remain agile and adaptive, focusing on innovation, collaboration, and market access.
• Balancing cost-control with innovation and quality is essential for long-term success.

Key Information

• VBP Scope: Includes high-value consumables, low-value consumables, equipment, and IVD reagents.
• Price Cuts: Ranges from 25-50% for IVD reagents to 50-70% for high-value consumables.
• Regulatory Reforms: DRG payment reforms are expanding, and VBP is expected to continue but more gradually.
• Innovation Support: The NMPA is accelerating approvals for innovative medical devices, with 451 applications in 2024.
• Private Healthcare Growth: Pilots for foreign-owned hospitals and commercial insurance coverage are increasing.
• Market Access Strategy: A 5-step approach is recommended, integrating regulatory, commercial, and technological considerations.

Conclusion

China's MedTech market is undergoing significant transformation, driven by cost-control reforms and a growing emphasis on innovation. While challenges persist, the opportunities for both local and multinational firms are substantial, especially with the development of private healthcare and the increasing recognition of innovative products. Companies that adapt strategically, invest in innovation, and localize their operations are best positioned to succeed in this dynamic environment.